Brought to you by 
BioNTech gets $270mm in Series A round
04 Jan 2018
Executive Summary
BioNTech AG (cancer immunotherapies and companion diagnostics) secured $270mm in Series A funding from lead investor the Redmile Group, Janus Henderson Investors, Invus, Fidelity Management & Research, and European family investors including the Struengmann Family Office. Struengmann and MIF Fond seeded BioNTech with $180mm back in 2008 when the company was formed.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioNTech gets $270mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice